The US FDA granted accelerated approval for Bristol-Myers Squibb's programmed cell death-1 (PD-1) inhibitor Opdivo (nivolumab) for the treatment of advanced melanoma more than three months earlier than expected.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?